SCOPUS 정보 검색 플랫폼

European Journal of Clinical Pharmacology

Volumn 61, Issue 4, 2005, Pages 315-316

Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity [1]

(3) Lee, Craig R a Hawke, Roy L a Pieper, John A b

a UNIVERSITY OF NORTH CAROLINA (United States)

b UNIVERSITY OF NEW MEXICO (United States)

Author keywords

CYP2C9; Polymorphism; Tolbutamide

Indexed keywords

CARBOXYTOLBUTAMIDE; CYTOCHROME P450 2C9; TOLBUTAMIDE;

AREA UNDER THE CURVE; BLOOD LEVEL; BLOOD SAMPLING; CALCULATION; DRUG CLEARANCE; DRUG METABOLISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMATION PROCESSING; LETTER; PHENOTYPE; PRIORITY JOURNAL; URINARY EXCRETION; VALIDATION PROCESS;

ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACOGENETICS; PHENOTYPE; TIME FACTORS; TOLBUTAMIDE;

EID: 21244465928 PISSN: 00316970 EISSN: None Source Type: Journal
DOI: 10.1007/s00228-005-0922-9 Document Type: Letter

Times cited : (1)

References (6)

1
- 0025264682
- Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
- Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411
- (1990) Clin Pharmacol Ther , vol.47 , pp. 403-411
- Veronese, M.E.¹ Miners, J.O.² Randles, D.³ Gregov, D.⁴ Birkett, D.J.⁵

2
- 0037214177
- Tolbutamide, flurbiprofen and losartan as probes of CYP2C9 activity in humans
- Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Tolbutamide, flurbiprofen and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84-91
- (2003) J Clin Pharmacol , vol.43 , pp. 84-91
- Lee, C.R.¹ Pieper, J.A.² Frye, R.F.³ Hinderliter, A.L.⁴ Blaisdell, J.A.⁵ Goldstein, J.A.⁶

3
- 0036881056
- Evaluation of CYP2C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes
- Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2002) Evaluation of CYP2C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin Pharmacol Ther 72:562-571
- (2002) Clin Pharmacol Ther , vol.72 , pp. 562-571
- Lee, C.R.¹ Pieper, J.A.² Hinderliter, A.L.³ Blaisdell, J.A.⁴ Goldstein, J.A.⁵

4
- 0036220552
- Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
- Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meise C, et al (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109
- (2002) Pharmacogenetics , vol.12 , pp. 101-109
- Kirchheiner, J.¹ Bauer, S.² Meineke, I.³ Rohde, W.⁴ Prang, V.⁵ Meise, C.⁶

5
- 2942620708
- Cytochrome P450 2C9 phenotyping using low-dose tolbutamide
- Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, et al (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165-171
- (2004) Eur J Clin Pharmacol , vol.60 , pp. 165-171
- Jetter, A.¹ Kinzig-Schippers, M.² Skott, A.³ Lazar, A.⁴ Tomalik-Scharte, D.⁵ Kirchheiner, J.⁶

6
- 4243052841
- Discovery of new potentially defective alleles of human CYP2C9
- Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-537
- (2004) Pharmacogenetics , vol.14 , pp. 527-537
- Blaisdell, J.¹ Jorge-Nebert, L.F.² Coulter, S.³ Ferguson, S.S.⁴ Lee, S.J.⁵ Chanas, B.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.